Sponsors (2)
The bill increases access to guideline-based genetic testing, preventive surgeries, and more frequent screenings for Medicare beneficiaries at high hereditary cancer risk—reducing out-of-pocket costs and improving prevention—while raising program costs and creating administrative burdens and potential variability in who receives covered care.
Medicare beneficiaries at high genetic or clinical risk will face lower out-of-pocket costs because Medicare will cover guideline-based germline testing, higher-frequency guideline screenings, and preventive surgeries.
Medicare will cover guideline-based germline mutation testing for beneficiaries with suspicious personal or family histories, improving access to clinically indicated genetic diagnosis.
Medicare will cover risk‑reducing (preventive) surgeries for beneficiaries identified as high genetic/clinical risk, which can lower future cancer incidence and treatment needs.
Expanding coverage to additional preventive surgeries and more frequent screenings will increase Medicare spending and federal costs.
More frequent screening for high-risk beneficiaries will raise the risk of false positives and lead to additional diagnostic procedures, anxiety, and downstream medical costs for some individuals.
If Medicare Administrative Contractors rely on a narrow set of recognized guideline organizations or apply the 'least restrictive' guideline inconsistently, beneficiaries may face variable or inequitable access and some evidence‑based tests or patients could be excluded.
Based on analysis of 4 sections of legislative text.
Requires Medicare coverage for germline genetic testing, guideline‑recommended risk‑reducing surgery, and relaxed high‑risk screening frequency for beneficiaries with pathogenic hereditary cancer mutations.
Official title: Amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.
Introduced September 10, 2025 by Lisa Murkowski · Last progress September 10, 2025
Expands Medicare coverage for people at increased hereditary cancer risk by adding inpatient germline mutation testing to covered hospital items, allowing payment for risk‑reducing surgery when supported by evidence‑based oncology guidelines, and requiring more frequent or relaxed limits on high‑risk cancer screening (at least annually) for beneficiaries with pathogenic germline cancer mutations. The law defines “germline mutation testing” tied to nationally recognized oncology guidelines and limits repeat testing to once per covered individual unless otherwise covered.